Kazia Therapeutics Announces Granting of Type C Meeting With FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

PR Newswire11/04 20:30

Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending

Benzinga10/26 07:50

Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women

PR Newswire10/15 19:32

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Benzinga10/03 20:06

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients With Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American...

PR Newswire10/02 20:45

Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium

PR Newswire09/23 20:30